Dr.ย Ji-Younย Han
B.S., M.D., M.S., Ph.D.
Principal Scientist & Chief, Lung Cancer Branch
corporate_fareNational Cancer Center, Goyang, South Korea
Ji-Youn Han
B.S., M.D., M.S., Ph.D.
Dr. Ji-Youn Han is a highly experienced medical oncologist and principal scientist at the National Cancer Center, Goyang, South Korea, where she serves as Chief of the Lung Cancer Branch and Principal Scientist in the Division of Precision Medicine. She completed her B.S., M.D., M.S., and Ph.D. at The Catholic University of Korea, followed by internal medicine residency and medical oncology fellowship training.
With over 30 years of clinical and research experience, Dr. Han has held successive leadership roles at the National Cancer Center since 2001, including Head of the Center for Lung Cancer, Head of the Division of Precision Medicine, and her current positions in the Lung Cancer Branch and Division of Hemato-Oncology. She also completed a visiting appointment at MD Anderson Cancer Center from 2003 to 2004. Her research encompasses EGFR-mutated non-small cell lung cancer, targeted therapy, immune checkpoint inhibitors, biomarker-driven treatment selection, ctDNA-based monitoring, and clinical trials for advanced and metastatic lung cancer. She was elected to the Presidential Advisory Council on Science & Technology in 2016โ2017 and led South Korea's National Precision Medicine project for lung cancer at the National Cancer Center.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an opinion from Dr. Han at the National Cancer Center, Goyang.
Why Consider Dr. Ji-Youn Han?
Dr. Han brings more than three decades of focused lung cancer expertise, combining leadership of the National Cancer Center's Lung Cancer Branch with internationally visible precision medicine research. She is especially relevant for patients with advanced NSCLC requiring biomarker-guided treatment planning.
Areas of Specialisation
Advanced lung cancer care driven by molecular science and precision medicine
Dr. Han's clinical and research work centres on non-small cell lung cancer and its molecular subtypes, integrating biomarker testing, targeted therapy, immunotherapy, and clinical trial access into individualised treatment planning.
EGFR-Targeted Therapy & Resistance
Molecularly guided treatment for EGFR-mutated and T790M-positive NSCLC.
- arrow_rightGefitinib, osimertinib, and lazertinib-based treatment planning
- arrow_rightctDNA monitoring to assess response and detect resistance
- arrow_rightManagement of EGFR T790M-positive advanced NSCLC
- arrow_rightERCC1 and molecular biomarker assessment for chemotherapy decisions
- arrow_rightComprehensive molecular profiling before initiating systemic therapy
Immunotherapy & Checkpoint Inhibition
Immune checkpoint inhibitor strategies for eligible advanced NSCLC patients.
- arrow_rightAnti-PD-1 antibodies for platinum-refractory, PD-L1-positive recurrent or metastatic NSCLC
- arrow_rightBlood tumour mutation burden assessment for atezolizumab selection in relapsed NSCLC
- arrow_rightReal-world outcomes research on checkpoint inhibitor therapy in Korean NSCLC populations
Advanced & Metastatic NSCLC
Comprehensive systemic treatment for advanced and metastatic lung cancer.
- arrow_rightChemotherapy protocols for advanced and metastatic non-small cell lung cancer
- arrow_rightALK-positive and squamous cell NSCLC management
- arrow_rightTranslational and clinical trial-based approaches for treatment-resistant disease
Procedures Performed
Clinical services and treatment approaches for lung cancer
Dr. Han delivers evidence-based lung cancer care at the National Cancer Center, integrating systemic therapy, targeted agents, immunotherapy, and clinical trial pathways into multidisciplinary treatment planning.
Medical Oncology for Lung Cancer
Medical OncologySystemic treatment planning and administration for advanced and metastatic non-small cell lung cancer.
Targeted Therapy
Targeted TherapyMolecularly guided therapy for EGFR-mutated and biomarker-selected lung cancer patients.
Immunotherapy
Medical OncologyImmune checkpoint inhibitor therapy for eligible advanced NSCLC patients.
Second Opinion & Complex Case Review
Second OpinionExpert second-opinion review for patients with advanced, treatment-resistant, or molecularly complex lung cancer.
Research & Publications
Peer-reviewed contributions to lung cancer science and precision medicine
Dr. Han has authored approximately 297 peer-reviewed papers with an h-index of 54 and over 18,600 citations (bibliometric estimates from independent sources). Her research spans EGFR inhibitors, biomarkers, immunotherapy, ctDNA, and clinical trials for advanced NSCLC.
Dr. Han's full publication list is available on PubMed and ORCID (0000-0001-5033-0006). A detailed profile can be provided on request through CancerFax.
Education & Training
Dr. Han completed all four of her degrees, B.S., M.D., M.S., and Ph.D., at the Catholic University of Korea, followed by residency and fellowship training at its affiliated teaching hospitals.
Clinical Experience
Dr. Han joined the National Cancer Center in 2001 and has held successive clinical, scientific, and administrative leadership roles across the Lung Cancer Branch, Center for Lung Cancer, Division of Precision Medicine, Division of Hemato-Oncology, and Center for Clinical Trials. She also completed a visiting appointment at MD Anderson Cancer Center from 2003 to 2004.
Languages & International
Dr. Han's official National Cancer Center profile does not list languages. English is used as the medium of her international publications and conference presentations. Verified spoken consultation languages are not publicly confirmed.
CancerFax can coordinate professional medical interpreter support for international patients seeking consultation at the National Cancer Center.
CancerFax can coordinate professional medical interpreter support for international patients where required.
How CancerFax Helps You Access Dr. Ji-Youn Han
CancerFax is a specialist cancer patient-navigation platform. We help international patients prepare structured medical summaries, assess treatment eligibility, and connect directly with Dr. Ji-Youn Han's team โ with full coordination from initial inquiry to consultation.
Medical Report Review
Free review of your pathology results, imaging, molecular profiling, and treatment history โ prepared as a structured clinical summary for Dr. Ji-Youn Han's team.
Treatment Eligibility Screening
CancerFax screens your case for eligibility for treatments and clinical programmes available through Dr. Ji-Youn Han before you travel, so you arrive with a clear pathway.
Case Submission
We coordinate direct case submission to Dr. Ji-Youn Han's department, including all documentation required for clinical review and appointment scheduling.
Appointment & Consultation Coordination
CancerFax manages appointment scheduling with Dr. Ji-Youn Han's team, confirming availability and aligning timelines with your travel plans.
Travel, Visa & Logistics Support
We prepare visa invitation letters, provide hospital-proximity accommodation guidance, and coordinate airport transfers for international patients.
Follow-Up & Continuity of Care
After your consultation or treatment, CancerFax facilitates communication between Dr. Ji-Youn Han's team and your home oncologist for seamless post-treatment follow-up.
Frequently Asked Questions About Dr. Ji-Youn Han
Dr. Han specialises in lung cancer, particularly non-small cell lung cancer (NSCLC), including EGFR-mutated NSCLC, EGFR T790M-positive NSCLC, ALK-positive NSCLC, PD-L1-positive recurrent or metastatic NSCLC, squamous cell lung cancer, and never-smoker lung adenocarcinoma.
Dr. Han is affiliated with the National Cancer Center in Goyang, Gyeonggi-do, Republic of Korea, where she serves as Chief of the Lung Cancer Branch and Principal Scientist in the Division of Precision Medicine.
CancerFax can coordinate medical-report review and consultation support for international patients seeking an expert opinion from Dr. Han at the National Cancer Center. Availability is subject to the hospital's current capacity and case acceptance criteria.
Submit your medical reports and imaging through CancerFax. The CancerFax team will review the documents, prepare the case summary, and coordinate the next steps with the National Cancer Center, subject to current availability.
A second-opinion request can be submitted through CancerFax with the patient's pathology reports, imaging, molecular test results, and treatment history. Dr. Han's expertise in EGFR-mutated NSCLC, targeted therapy resistance, immunotherapy eligibility, and precision oncology makes her well suited for complex second-opinion cases. The final consultation format depends on the hospital's process and availability.
Yes. Dr. Han is listed on ClinicalTrials.gov as the responsible party for a completed NSCLC study (NCT00452244) sponsored by the National Cancer Center, Korea. She has also been a lead author on results from the LASER201 trial investigating lazertinib in EGFR T790M-positive advanced NSCLC, and has contributed to Korean Cancer Study Group immunotherapy trials.
Dr. Han's published research and clinical work includes EGFR tyrosine kinase inhibitors such as gefitinib, osimertinib, and lazertinib; immune checkpoint inhibitors including anti-PD-1 and anti-PD-L1 agents; platinum-based chemotherapy with ERCC1 biomarker guidance; and blood tumour mutation burden testing for immunotherapy selection in advanced NSCLC.
Connect with Ji-Youn Han Today
Share your medical reports for a free preliminary review. Our patient coordinators will help you understand your options and arrange a direct consultation.
Medical Disclaimer: Information on this page is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making any medical decisions.